Bristol-Myers Squibb in its $90 billion acquisition of Celgene and its related $13.4 billion divesture of Celgene’s OTEZLA® program to Amgen
Bristol-Myers Squibb in its defense against Starboard Value’s proxy contest opposing Bristol-Myers Squibb’s $90 billion acquisition of Celgene
Clearwater Analytics in its new investment from Permira, Warburg Pincus and Durable Capital, with Welsh Carson remaining a majority stockholder
Colfax Corporation in its $3.2 billion acquisition of DJO Global
Fox Corporation in its $397 million acquisition of Credible Labs
Harland Clarke Holdings in its sale of Scantron Corporation to Transom Capital Group
KPS Capital Partners in its acquisition of AM General LLC
Lincolnshire Management in its investment in Schumacher Electric Corporation
Norwegian Cruise Line Holdings Ltd. in its PIPE investment from L Catterton as part of Norwegian’s multi-tranche financing for aggregate proceeds of up to $2.4 billion
Sentinel Capital Partners in its acquisition of New Era Technology, Inc., a technology solutions provider
The Jordan Company, L.P. in its acquisition of Vyne, a provider of software solutions for secure health information exchange and electronic healthcare communication management
WellCare Health Plans in its $17.3 billion acquisition by Centene Corporation
